The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cytokine market reached a value of US$ 76.67 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 121.25 Billion by 2027, exhibiting a CAGR of 7.80% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
A cytokine refers to a group of proteins, peptides, or glycoproteins released by specific cells to control the growth and activity of the immune system and blood cells. It can regulate immunity, inflammation, and hematopoiesis on account of its high-affinity picomolar concentrations. It is usually injected under the skin or into muscles or veins to help prevent or manage chemotherapy side effects and treat cancer. It also boosts anti-cancer activities by sending signals that make abnormal cells die and normal cells live longer. Presently, it is gaining widespread adoption in cell and gene therapy for the expansion and differentiation of various cell types, ex vivo cultures, and other therapeutic approaches.
The coronavirus disease (COVID-19) is transmitted via droplets that can induce the excessive production of proinflammatory cytokines and lead to acute respiratory distress syndrome (ARDS) aggravation and tissue damage. As tissue damage can result in multi-organ failure and death, there is a rise in the demand for solutions that target cytokines to manage patients, improve survival rates, and reduce mortality. Apart from this, the increasing prevalence of cancer, in confluence with the escalating demand for minimally invasive surgeries (MIS) that provide less post-operative pain and complications and faster recovery time, is contributing to the market growth. Moreover, as cytokines act as diagnostic, prognostic, and therapeutic agents and biomarkers for health and diseases, they are gaining traction in diverse functions, including immune cell differentiation, inflammation, angiogenesis, tumorigenesis, neurobiology, and viral pathogenesis. Besides this, the rising cases of atopic dermatitis (AD), a recurrent, chronic, and inflammatory skin disease that processes with severe itchiness, is driving the demand for new cytokines in the pathogenesis of AD and developing improved therapeutic targets.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cytokine market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on cytokine type, therapeutic application and end user.
Breakup by Cytokine Type:
Breakup by Therapeutic Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Abcam plc, Amgen Inc., Applied Biological Materials Inc. (abm), Bio-Techne Corporation, F. Hoffmann-La Roche AG, GenScript Biotech Corporation, Randox Laboratories Ltd., Thermo Fisher Scientific Inc. and UCB S.A.
|Base Year of the Analysis||2021|
|Segment Coverage||Cytokine Type, Therapeutic Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||AbbVie Inc., Abcam plc, Amgen Inc., Applied Biological Materials Inc. (abm), Bio-Techne Corporation, F. Hoffmann-La Roche AG, GenScript Biotech Corporation, Randox Laboratories Ltd., Thermo Fisher Scientific Inc. and UCB S.A.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028
Congestive Heart Failure Drugs Market by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
Gastric Cancer Drugs Market by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at